Would you offer neoadjuvant pembrolizumab to a TNBC patient with multiple pulmonary nodules and bilateral hilar adenopathy secondary to asymptomatic sarcoidosis (biopsy proven)?  

Given the potential benefits of the addition of pembrolizumab to neoadjuvant chemotherapy in clinical stage IIB-III TNBC, I would favor doing so [but not for clinical stage I or small IIA (T<3 cm N0), in whom the potential benefits would be more modest], but I would monitor the patient closely fo...